Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × FED × relugolix × Clear all

Phase

Status

Sponsor Class

OTHER 16 INDUSTRY 3 NETWORK 1 FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1 Neoplasm Metastasis 1

Interventions

pembrolizumab 3 enzalutamide 2 Testosterone 2 Itraconazole 2 Exercise 2 zanubrutinib 1 venetoclax 1 stenoparib 1 relugolix 1 olaparib 1 nilutamide 1 ibrutinib 1 histrelin 1 capivasertib 1 bicalutamide 1 apalutamide 1 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1 acalabrutinib 1 abiraterone 1 Waiting Lists 1 Triptorelin Pamoate 1 Temozolomide 1 Surveys and Questionnaires 1 Radiosurgery 1 Prednisone 1 Pluvicto 1 PM 01183 1 Nutritional Status 1 Nivolumab 1 Methylprednisolone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04787744 2026-04-08

VA STARPORT

VA Office of Research and Development

Phase 2/3 Recruiting

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡